Seres Therapeutics to Present at H.C. Wainwright BioConnect Conference
Event summary
- Seres Therapeutics will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 3:30 p.m. ET.
- The presentation will be available via live webcast and replay on the company’s website.
- Seres Therapeutics is a clinical-stage biotechnology company focused on live biotherapeutics for inflammatory and immune diseases.
- SER-155, a key pipeline candidate, has received Breakthrough Therapy and Fast Track designations and is Phase 2 ready pending funding.
- SER-603 is in development for inflammatory bowel disease, targeting the gastrointestinal microbiome.
The big picture
Seres Therapeutics' participation in the H.C. Wainwright BioConnect Investor Conference underscores its efforts to engage with investors amid a critical phase in its pipeline development. The company's focus on live biotherapeutics positions it within the broader trend of microbiome-based therapies, which are gaining traction in treating inflammatory and immune diseases. The strategic divestment of VOWST™ to Nestlé Health Science highlights the company's ability to monetize assets while advancing its core pipeline.
What we're watching
- Funding Progress
- Whether Seres Therapeutics can secure the necessary funding to advance SER-155 into Phase 2 trials.
- Pipeline Development
- The pace at which SER-603 progresses through development for inflammatory bowel disease.
- Investor Sentiment
- How the market reacts to the company’s strategic updates and pipeline progress.
Related topics